MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.yebeh.2017.02.028

Медицинская библиотека · Epilepsy & behavior : E&B · 2017

Efficacy and safety of eslicarbazepine acetate monotherapy for partial-onset seizures: Experience from a multicenter, observational study.

Toledano Rafael, Jovel Camilo Espinosa, Jiménez-Huete Adolfo, Bayarri Pau Giner, Campos Dulce, Gomariz Elena López, Giráldez Beatriz González, García-Morales Irene, Falip Mercé, Agredano Paula Martínez, Palao Susana, Prior María José Aguilar Amat, Pascual María Rosa Querol, Navacerrada Francisco José, González Francisco Javier López, Ojeda Joaquín, Sáez Aránzazu Alfaro, Bermejo Pedro Emilio, Gil-Nagel Antonio

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод в очереди

Аннотация

Eslicarbazepine acetate (ESL, Aptiom™) is a once-daily anticonvulsant, approved as adjunctive treatment of partial-onset seizures (POS). Historical-controlled trials investigating the use of ESL as monotherapy have demonstrated a favorable efficacy and tolerability profile in patients with POS. This prospective, non-interventional study recruited POS patients in 17 hospitals in Spain. After a 3-month baseline period, ESL therapy was initiated as 400mg QD and up-titrated to an optimal maintenance dose based on clinical response and tolerance. The incidence of seizures was assessed via seizure calendars and the nature and severity of adverse events (AEs) were also recorded. A total of 117 patients (aged 9-87years) enrolled in the study and were treated with ESL at either 400mg/day (3.4% patients), 800mg/day (61% patients), 1200mg/day (27.1% patients) or 1600mg/day (8.5% patients). At 3months, 82.0% (n=72) of patients achieved a ≥50% reduction in seizure frequency, compared to 79.7% (n=67) of patients at 6months and 83.0% (n=49) at 12months. Patients who suffered secondary generalized tonic-clonic (SGTC) seizures had seizure-free rates of 71% (n=27), 69.6% (n=29), and 72.7% (n=16) at 3, 6, and 12months, respectively. Overall, 18 patients (15.3%) reported AEs of instability and dizziness (n=9), somnolence (n=3), mild hyponatremia (n=3), headache (n=1), hypertriglyceridemia (n=1), and allergic reaction (n=1), which caused ESL discontinuation of ESL treatment. ESL is effective and well tolerated as monotherapy for patients with POS, which supports previous findings. Early use is supported by its frequent use as monotherapy in this study and lack of severe side effects.

Для цитирования: Toledano Rafael, Jovel Camilo Espinosa, Jiménez-Huete Adolfo, Bayarri Pau Giner, Campos Dulce, Gomariz Elena López, Giráldez Beatriz González, García-Morales Irene, Falip Mercé, Agredano Paula Martínez, Palao Susana, Prior María José Aguilar Amat, Pascual María Rosa Querol, Navacerrada Francisco José, González Francisco Javier López, Ojeda Joaquín, Sáez Aránzazu Alfaro, Bermejo Pedro Emilio, Gil-Nagel Antonio. Efficacy and safety of eslicarbazepine acetate monotherapy for partial-onset seizures: Experience from a multicenter, observational study.. Epilepsy & behavior : E&B. 2017. DOI: 10.1016/j.yebeh.2017.02.028.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.